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A Metabolic Enzyme of the Short-Chain
Dehydrogenase/Reductase Superfamily May
Moonlight in the Nucleus as a Repressor
of Promoter Activity
Nelli G. Markova1, Adriana Pinkas-Sarafova1 and Marcia Simon1
Transcriptional repression often depends on the action of recruited co-repressor complexes with intrinsic
enzymatic activities. The composition of these complexes depends on the nicotine amide dinucleotide
co-factors and is thus directly reflective of the metabolic state of the cells. This study provides evidence that
an enzyme, hRoDH-E2, with cytoplasmic phosphorylated and reduced forms of NAD-dependent retinol
dehydrogenase activity may function in the nucleus as a transcriptional repressor. By using the promoter of the
epidermal late differentiation marker profilaggrin as a model, we show that both in vivo and in vitro the protein
is recruited over the promoter. hRoDH-E2 represses profilaggrin promoter activity by altering the function of
other activators, such as Sp1. The repressive function is associated with the ability of nuclear hRoDH-E2 to
modulate the acetylation/deacetylation activity in the vicinity of transcription initiation site. These findings add
hRoDH-E2 to the small group of metabolic enzymes, which, by being recruited over promoter regions, could
directly link the cytoplasmic and nuclear functions within the cell.
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INTRODUCTION
A growing number of examples emphasize the possibility that
‘‘moonlighting’’ by proteins (i.e. taking two or more jobs, a
term coined by Jeffery (1999)) is indeed the norm rather than
the exception. Moonlighting proteins may be metabolic and
protein-modifying enzymes, structural and ribosomal proteins,
ion channels and exchangers, chaperones. The list of the
‘‘other’’ function(s) that they may perform is equally diverse.
They include, but are not limited to, signal transduction,
transcriptional regulation, control of growth and differentiation,
tumor suppression, DNA repair, and apoptosis (for reviews see
Jeffery, 1999, 2003a, b, 2004; Moore, 2004; Sriram et al.,
2005). A number of factors may simultaneously or indepen-
dently determine which job a moonlighting protein will be
performing at a given time, including differential localization in
subcellular compartments and cell type-specific expression of
the moonlighting protein itself or of proteins with which it
forms multiprotein complexes, changes in ligand, substrate,
and co-substrate concentrations. Since often the moonlighting
functions involve different but overlapping interaction faces,
the choice of job may also depend on post-translational
changes in response to particular cellular cues.
There are several advantages that multitasking proteins can
provide to the cell. First, this is a frugal mechanism that saves
the cell energy, resources, and space. Second, it enables the
cell to quickly respond to changing needs. Third, it can be a
potent feedback regulatory tool. Finally, moonlighting proteins
expand the regulatory networks of the cell and may serve as
converging points and switches between different pathways.
Examples of the various ways in which protein multitasking
increases the cellular complexity are discussed in the reviews
cited above and the references therein.
In the present paper, we describe a so far hidden
moonlighting activity in a metabolic enzyme of the short
chain dehydrogenase/reductase superfamily. Previously we
characterized the enzyme, hRoDH-E2, in normal human
epidermal keratinocytes (NHEKs) as an abundant micro-
somal retinol dehydrogenase with a preference to NADP as a
co-substrate (Markova et al., 2003). The biochemical proper-
ties and the differential expression of hRoDH-E2 in the strata
where retinoic acid (RA) signaling is critical for epidermal
homeostasis supported a conclusion that hRoDH-E2 may
be a major player in the production of RA in epidermal
keratinocytes under physiological conditions. It appears that
it may function as a retinol dehydrogenase in tracheobron-
chial (Soref et al., 2001) and colon (Jette et al., 2004)
epithelium, as well. In in vitro studies Chetyrkin et al. (2001)
found that the liver analogue of hRoDH-E2 was much more
efficient as a 3a-hydroxysteroid dehydrogenase but with
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a preference to NAD(H) as a co-substrate. Our results also
showed that the retinol dehydrogenase activity of the enzyme
is cell type specific (Markova et al., 2003). Now we provide
evidence that hRoDH-E2 may also serve in the nucleus to
downregulate promoter activity.
Transcriptional repression can be achieved directly,
through binding of the repressor to target DNA sequences,
or indirectly, via modulation of the regulatory activity of
DNA-bound proteins through their association with co-
repressors, which mediate the inhibitory effects (see Johnson,
1995; Knoepfler and Eisenman, 1999; Maldonado et al.,
1999; Tyler and Kadonaga, 1999; Marmorstein, 2002; Denu,
2003; Kumar et al., 2004 and references therein). The overall
promoter activity is ultimately determined by the coordinated
interactions of several of these co-repressors within the
relevant chromatin structure (Yang and Seto, 2003; Kumar
et al., 2004). The co-repressors include proteins with (some-
times several) intrinsic enzymatic activities that catalyze a
variety of covalent modifications (see Davie and Spencer,
1999; Ng and Bird, 2000; Nakatani, 2001; Shall, 2002;
Denu, 2003, 2005; Yang and Seto, 2003; Zhang, 2003; Davie
and Dent, 2004; Kubicek and Jenuwein, 2004; Shi et al.,
2004; Dokmanovic and Marks, 2005). This, in turn, results
in site-specific chromatin remodeling (Kumar et al., 2004).
The histone acetyltransferases and histone deacetylases are
two such groups of enzymes that determine the pattern of
reversible acetylation of histone and non-histone proteins
and thereby play a critical role in the regulation of gene trans-
cription. In general, increased acetylation is associated with
transcriptional activation, whereas hypoacetylation is more
often linked to repression (see Ng and Bird, 2000; Nakatani,
2001; Yang and Seto, 2003; Denu, 2003, 2005; Dokmanovic
and Marks, 2005). Based on homology in their catalytic sites
and sensitivity to inhibitors such as trichostatin A (TSA),
suberoylanilide hydroxamic acid (SAHA) and sodium buty-
rate, three classes of deacetylases have been described. Class
I/II enzymes are inhibited by TSA, suberoylanilide hydro-
xamic acid and butyrate. Class III enzymes are insensitive
to TSA, suberoylanilide hydroxamic acid, and butyrate
and are unique in their absolute dependence on NAD as a
co-enzyme. At least in part, the activities of all three classes
of deacetylases are regulated by protein/protein interactions.
Because most histone acetyltransferases and histone deace-
tylases do not encompass DNA-binding domains, other
nuclear proteins with intrinsic DNA-binding activity are
required for their proper recruitment over specific regulatory
regions (see Nakatani, 2001; Sengupta and Seto, 2004 and
references therein). In addition, class III enzymes are regu-
lated by the availability of metabolic co-factors (see Denu,
2005; Dokmanovic and Marks, 2005).
Our results indicate that hRoDH-E2 does not bind directly
to DNA. Rather, its repressive function is achieved through
protein/protein interactions, which, in the case of the
epidermal marker profilaggrin, involve the transcriptional
activator Sp1. As part of the native chromatin, hRoDH-E2
interacts with Sp1 and interferes with the Sp1-dependent
activation of the profilaggrin promoter by modulating the
acetylation in the vicinity of the transcription-initiation site.
RESULTS
hRoDH-E2 presence in the nucleus
Like many proteins belonging to the short chain dehydro-
genase/reductase superfamily, hRoDH-E2 is associated with
microsomal membranes where, using pyridine dinucleotides
as co-substrates, it functions as a retinol- (Markova et al.,
2003) or hydroxy-steroid (Chetyrkin et al., 2001) dehydro-
genase/reductase. Consistent with the biochemical data,
confocal microscopy of NHEK stained with hRoDH-E2
specific antibody showed colocalization of the protein with
concanavalin A – a marker of the endoplasmic reticulum
(Figure 1a–c). However, the confocal microscopy also
revealed that hRoDH-E2 is not an exclusively cytoplasmic
protein. In about 40% of the keratinocytes hRoDH-E2-
positive signal was also observed in the nucleus, colocalized
with the nuclear export protein CRM1 (Figure 1d–f). Likewise,
staining with a V5-specific antibody detected a nuclear
translocation of hRoDH-E2 in keratinocytes transfected with
a V5-tagged hRoDH-E2 expression vector (Figure 1g and h).
Nuclear colocalization of hRoDH-E2 and CRM1 was
detected in the epidermal tissue as well, especially in the
more differentiated upper spinous layers (Figure 1k and l). In
addition, we observed that a relatively small amount of the
protein is present at the plasma membrane of all cells (Figure
1d, asterisk) and, accordingly, we found that both in NHEK
(Figure 1l and m) and in the epidermis (Figure 1o and p) it
colocalized with wheat germ agglutinin.
hRoDH-E2 represses the activity of epidermal promoters
During our studies of the retinol-metabolizing activity of the
protein in live NHEK we noticed that forced expression
hRoDH-E2, while activating transcription from a RA-respon-
sive construct, downregulated the expression of the parent
reporter Dtk-CAT into which the RA response element
was cloned. The expression of CAT from this reporter was
controlled by the minimal thymidine kinase promoter Dtk
(50/þ 50), consisting of only a TATA box and a short GC-
rich sequence (Lee et al., 1996). Together with the nuclear
localization data, these observations prompted us to explore
whether hRoDH-E2 can affect promoter activity independent
of its impact on RA production. We co-transfected NHEK
with hRoDH-E2 expression vector and reporter constructs
in which the expression of CAT is under the control of either
profilaggrin (354/þ 9) or keratin K5 (705/þ6) (Rossi
et al., 1998) promoter regions. We chose these particular
promoters since they control the expression of genes, which
are active at the sites where hRoDH-E2 expression is at its
maximum – profilaggrin in the granular layer and K5 in
the basal cells (Markova et al., 2003). In NHEK both K5
and profilaggrin transcription is RA sensitive. The K5
control region that we used harbors a functional RA response
element (Radoja et al., 1997), whereas the profilaggrin
promoter region does not encompass such motifs (Presland
et al., 2001). We also included the Dtk-CAT reporter, which is
not sensitive to RA (Markova et al., 2003). Forced expression
of hRoDH-E2 (Figure 2a, shaded bars) reduced the activity
of all three promoters more than 2-fold. In contrast, co-
transfection with another epidermal retinol dehydrogenase of
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the short chain dehydrogenase/reductase family – hRoDH-E
(Figure 2a, white bars), cloned in the same expression vector
(Jurukovski et al., 1999) and expressed to a similar level
(Figure 2b), had no effect on the reporters’ activity.
Considering that hRoDH-E2 and hRoDH-E share 70%
homology and proven retinol dehydrogenase activities in
NHEK under the present experimental conditions (Jurukovski
et al., 1999; Markova et al., 2003), the comparable down-
regulation of both RA-insensitive profilaggrin and Dtk, and of
RA-sensitive K5 reporters indicate that the transcriptional
repression was specific for hRoDH-E2 and most likely was
not related to RA production. This conclusion was further
supported by the observation that hRoDH-E2 mutant
constructs, in which the enzyme active site has been mutated
or deleted (striped bars), were equally effective in repressing
profilaggrin promoter activity. Finally, ability of hRoDH-E2 to
repress epidermal transcription in an RA-independent mode
was suggested by its effect on the expression of the recently
characterized epidermal retinyl ester hydrolase GS2 (Gao
and Simon, 2005), which is RA insensitive (Gao J and Simon
M, unpublished results.). In NHEK transduced with retro-
viruses expressing hRoDH-E2, GS2 mRNA levels are reduced
by 2-fold, compared to the control cells, whereas transduc-
tion with retroviruses encompassing hRoDH-E2 siRNAs led
to a 3-fold higher GS2 mRNA production (Markova NG,
Pinkas-Sarafova A, Karaman-Jurukovska N and Simon M,
unpublished results).
hRoDH-E2 silencing is mediated through specific promoter
sequences
The activity of profilaggrin promoter is modulated by
interactions of activator protein 1 (AP1) (Jang et al., 1996)
and epidermal POU-domain proteins (Jang et al., 2000) at
their cognate AP1- and Oct-binding sites (Figure 3a). Our
unpublished results (Markova NG, Pinkas-Sarafova A, Karaman-
Jurukovska N and Simon M, unpublished results) indicate that
the sequences designated S-100, S-70, S-50, and S-35 are
also involved in the regulation. To explore whether the
hRoDH-E2-driven repression was transmitted through any of
these motifs, we co-transfected NHEK with hRoDH-E2
and profilaggrin-CAT reporters in which the transcription
factor-binding sites were mutated to abolish the respective
interactions. With the exception of S-70 and S-35, hRoDH-E2
downregulated the expression of the mutant and the wild-
type reporters to a similar extent (Figure 3b). Compared to the
wild type, the CAT activity of S-70 and S-35 mutant reporters
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Figure 1. Nuclear localization of hRoDH-E2. (a–r) NHEK grown in culture (bars¼ (a, d, and l) 2mm) and frozen sections of foreskin epidermis (bars¼ (i and
q)¼12 mm) were incubated with hRoDH-E2-specific antibody and visualized with AlexaFluor 596-conjugated secondary antibody (red). (b) Concanavalin A and
(m and p) wheat germ agglutinin were detected after incubation of the samples with the respective compounds, conjugated to AlexaFluor 488. Field (c) is a
merge of (a and b), and shows the co-staining with concanavalin A in the endoplasmic reticulum. CRM1-specific and AlexaFluor 488-conjugated secondary
antibodies were used to monitor the localization of nuclear CRM1 in (e and h) NHEK and (j) frozen epidermal sections. Field (f) is a merge of (d and e), field (k) is
a merge of (i and j). (g) Signal from V5-tagged hRoDH-E2 transfected in NHEK and detected with AlexaFluor 596-conjugated goat anti-mouse antibody;
(h) merge of (g) and the signal after staining the same field with anti-CRM1. Field (n) is a merge of (l and m); (o) is a merge of (p) and the same section stained
with anti-hRoDH-E2 antibody (not shown). Fields (i–k and o and p) are epifluorescent pictures, fields (a–h and l–m) are the stacked Z-slices from con-focal
microscopy. Fields (q and r) illustrate the epifluorscence from the epidermal sections and the cultured cells, respectively, stained with DAPI and AlexaFluor
596-anti-chicken antibody only. The cells in field (s) were consecutively incubated with AlexaFluor 596-anti-chicken and AlexaFluor 488-anti-rabbit secondary
antibodies. The asterisk in (d) depicts the plasma membrane staining in the cultured cells. The white color (assigned) in the confocal pictures (c, f and n), and the
yellow color in (h, k, and o), represent the colocalization of hRoDH-E2 and the various markers of subcellular compartments.
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was reduced by 40 and 70%, respectively, but forced
expression of hRoDH-E2 only marginally repressed their
transcription (compare the respective black and striped
bars). Together these results indicate that while AP1, Oct,
and all four S-motifs associate with positive regulators, S-70
and S-35 are involved in hRoDH-E2-dependent negative
regulation, as well.
hRoDH-E2 is recruited over profilaggrin promoter
The following evidence suggests that the silencing stemmed
from in situ interactions of hRoDH-E2 with components
of the nuclear transcription machinery. First, in an in vitro
experiment NHEK nuclear proteins were captured over
profilaggrin promoter (147/þ 9)- or exon II-coated strepta-
vidin-magnetic beads, and analyzed for the presence of
hRoDH-E2 (Figure 4a). Comparison between the bound
fractions shows that at least 10-fold more hRoDH-E2 was
recruited over the promoter-coated beads (lane 3) compared
to exon II-coated beads (lane 11). When present in 100-fold
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Figure 2. Forced expression of hRoDH-E2 represses promoter activity in
NHEK. (a) NHEK were co-transfected with reporter plasmids, in which the
transcription of CAT was controlled by human profilaggrin promoter region
354/þ 9, keratin K5 promoter region 705/þ6 or a minimal Dtk promoter
(þ50/50), and expression vectors for hRoDH-E2 (shaded bars), hRoDH-E
(white bars) or the empty expression vector pcDNA3.1 (black bars). The wide
and narrow-striped bars represent co-transfections with active site-mutant and
deletion hRoDH-E2 constructs, respectively. For each reporter construct the
results are presented as a percent of the CAT activity in the mock-transfected
cells. Compared to the activity of a mock co-transfected promoterless CAT
construct (2000 c.p.m./mg), the activities of profilaggrin-, K5-, and Dtk-CAT
were 50-, 10-, and 2-fold higher, respectively. (b) Expression levels of
exogenous, V5-tagged hRoDH-E2 (E2 in lane 2 or wild type (wt) in lane 4) and
hRoDH-E (E, lane 3), detected with V5-specific antibody (upper panel), and
of total hRoDH-E2, detected with hRoDH-E2-specific antibody (lower panel),
in NHEK transfected with mock (lane 1), wt (lanes 2 and 4) and mutant
hRoDH-E2 (lanes 5 and 6) and with wt hRoDH-E (lane 3). The expression
constructs are shown on the top, the detecting antibodies on the right. AS-m
and DC represent expression constructs in which the catalytic site has been
mutated or deleted, respectively.
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Figure 3. hRoDH-E2 represses profilaggrin promoter in a sequence-specific
manner. (a) Schematic representation of profilaggrin region between positions
150 and þ 49, encompassing the S-motifs, the AP1, and Oct recognition
motifs; the arrow marks the transcription initiation site. (b) hRoDH-E2-loaded
(striped bars) or empty (black bars) expression vectors were transfected in
NHEK together with wild type (wt) or the designated mutant CAT reporters.
Each mutation destroyed the respective recognition motif within the context
of the region and prevented its interactions with nuclear proteins. For each
reporter the transient CAT activity is presented as a percentage of the activity
of the mock-transfected wt construct.
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Figure 4. Nuclear hRoDH-E2 is recruited over profilaggrin promoter and
represses its in vitro transcription activity. (a) hRoDH-E2 detected by
Western blotting in the input (IP, lane 1), the non-bound (NB, lanes 2 and 10)
and the bound (b, lanes 3–9, 11) fractions (10 mg each) obtained after
incubation of NHEK extract with profilaggrin promoter (147/þ 9), or exon
II-coated streptavidin magnetic beads. Lanes 4–6 represent the amount of
hRoDH-E2 bound to the promoter after preincubation of the extract with a
100-fold molar excess of the designated oligonucleotides. Lanes 7–9 show
hRoDH-E2 retention after preincubation of the extract with hRoDH-E2
antibody (E2), NIS and an un-related antibody (URA), respectively.
(b) hRoDH-E2 and gastrin-releasing peptide 78 levels in the cytoplasmic
(CE) and nuclear (NE) extracts from NHEK and HeLa cells. (c) Profilaggrin-
(PF) and Dtk-CAT (Dtk) in vitro transcripts produced in un-treated HeLa
nuclear extracts (lane 1) or after pre-treatment with NIS (lane 2) and
hRoDH-E2-specific IgYs (lane 3).
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molar excess, oligonucleotides S-70 (lane 4) and S-35 (lane 5)
competed with the captured promoter for hRoDH-E2 reten-
tion, while the corresponding mutant (e.g. lane 6) and a
number of un-related oligonucleotides (e.g. AP1, Oct, NF-kB,
data not shown) had no effect. Likewise, preincubation of the
nuclear extract with hRoDH-E2 antibody interfered with the
recruitment (lane 7), while the amount retained after
preincubation with non-immune serum (NIS, lane 8) or with
several un-related antibodies such as c-jun, Oct1, ets (data
not shown), and NF-kB p50 (shown as URA, lane 9) was
similar to the control (lane 3).
Second, we used the CAT reporters under the control of
profilaggrin (–354/þ9) and Dtk (50/þ50) promoters as
templates for in vitro RNA synthesis by a transcriptionally
competent HeLa nuclear extract. This region of the profilag-
grin promoter is active in HeLa cells (Jang et al., 1996). As
seen in Figure 4b, the amount of nuclear hRoDH-E2 in the
HeLa extract was comparable to that in the NHEK nuclear
extract and in both cases was 40–50% that found in the
cytoplasm. While the cytoplasmic extracts showed compar-
able signals for hRoDH-E2 and gastrin-releasing peptide
78 – a marker of the endoplasmic reticulum, in the nuclear
extracts the gastrin-releasing peptide 78 signal was barely
detectable (3–5% of the respective cytoplasmic signals),
thereby excluding any significant contribution by perinuclear
contamination. Lane 1 in Figure 4c shows the profilaggrin-
and Dtk-CAT transcripts generated by HeLa nuclear extract
in 1 hour. Similar amounts were transcribed from both
templates by extract that had been preincubated with
non-immune chicken serum (lane 2). In contrast, about
3-fold more profilaggrin- and Dtk-CAT transcripts were
detected upon preincubation with hRoDH-E2-specific anti-
body (lane 3), thus implicating nuclear hRoDH-E2 in
transcriptional repression.
hRoDH-E2 is associated with the S-35 and S-70 motifs
Despite the retention over the promoter we were unable to
detect direct interaction of hRoDH-E2 with DNA (data not
shown). Therefore, nuclear hRoDH-E2 more likely down-
regulated profilaggrin promoter activity through interactions
with other DNA-binding regulatory proteins. Preliminary
results indicated that the S-motifs, which bear homology to
the recognition sequences of the Sp1/Kruppel-like factor
proteins (GT, CA, or GC boxes, for reviews see Philipsen and
Suske, 1999; Turner and Crossley, 1999), could interact with
transcription factor Sp1. These interactions left specific
footprints over the promoter region and created sites of
increased susceptibility to DNase I (Markova NG, Pinkas-
Sarafova A, Karaman-Jurukovska N and Simon M, unpub-
lished results). These observations suggested that Sp1 bound
at S-70 and S-35 could be one of the protein partners of
hRoDH-E2. We tested this in bandshift experiments. Both
S-35- (Figure 5a, lane 1) and S-70- (lane 2) labeled
oligonucleotides interacted with NHEK nuclear extract to
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Figure 5. hRoDH-E2 participates in protein/protein interactions over profilaggrin promoter in vitro. (a) Bandshift profiles of oligonucleotides S-35 (lane 1) and
S-70 (lane 2) with NHEK nuclear proteins; the arrows point to the slow migrating complexes A and B. (b) The specificity of the S-70 complexes as revealed in
competition with the designated fold molar excess of unlabeled wild type (wt) (lanes 1–5) or mutant (lanes 6–8) S-70 oligonucleotides. (c) Sensitivity of
complexes A and B to the presence of 100-fold molar excess of unlabeled dI/dC (lane 1), the designated wt or mutant oligonucleotides (lanes 2–6) and antibodies
(7–11). The extract used in the binding reaction in lane 10 was derived from NHEK-transfected with V5-tagged hRoDH-E2 expression vector. The arrowheads
point to the supershifts containing the Sp1, V5, and hRoDH-E2 antibodies. We were unable to ascertain the specificity of the fast migrating material, marked
with the asterisks, and, therefore, it was not further investigated. (d) Shift-Western profiles of oligonucleotides S-35 (lanes 2, 5, 8, 11, and 14) and S-70 (lanes 3,
6, 9, 12, and 15). No DNA was included in the binding reactions in lanes 1, 4, 7, 10, and 13. The nitrocellulose replicas (1–3, 4–6, 10–12, and 13–15) were
analyzed with the designated antibodies. The nylon replica (lanes 7–9) shows the retardation profiles of the labeled probes. The arrows on the right indicate the
mobility of complexes A and B, those on the left mark the signals obtained with the designated antibodies.
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form complexes (A and B) that were similar in mobility but
different in intensity. We confirmed the specificity of
complexes A and B by carrying out the bandshift reactions
in the presence of various competitors and antibodies. Figure
5b and c illustrate the results with S-70. We observed that
the assembly of both complexes A and B was sensitive to
the presence of excess un-labeled S-70 oligonucleotide; the
intensities of the corresponding retarded bands were gradu-
ally reduced upon increasing concentrations of the compe-
titor (Figure 5b, lanes 1–5). In contrast, neither complex was
affected by the presence of mutant S-70 oligonucleotides,
even at the highest concentrations (lanes 6–8). At the same
time the assembly of a non-specific, faster migrating
complex, marked with an asterisk, remained consistently
unperturbed by excess of either wild-type or mutant
competitors. Complexes A and B were resistant to 100-fold
molar excess of dI/dC (Figure 5c, lane 1) and to NIS (lane 9).
Similar to S-70 (lane 2), both complexes were competed by
100-fold molar excess of unlabeled wild-type (lane 3) but not
mutant (lane 4) S-35. In agreement with our preliminary
observations, complex A was competed out by excess of
consensus Sp1 (lane 5) but was resistant to competition with
mutant Sp1 oligomers (lane 6). The participation of Sp1
protein in complex A formation was confirmed by the
complete supershift of the band by an antibody against Sp1
(lane 7). Neither Sp1 consensus oligonucleotides, nor Sp1-
specific antibody interfered with the formation of complex B.
These results suggested that the two S-motifs also interact
with other DNA-binding proteins, which are not related to
Sp1. In addition to their similarity to the GT/CA boxes, the
S-motifs showed homology to the recognition sequences
(YRTGDGAD) of the Notch effector RBP-Jk (Tun et al., 1994).
Moreover, a silencing element homologous to S-70 has been
identified within the complement receptor 2 (CR2/CD21)
gene and shown to encompass overlapping Sp1 and RBP-Jk
motifs. Mutations, analogous to those preventing mutant
S-70 to compete for complexes A and B formation, were
found to prevent binding to both Sp1 and RBP-Jk (Makar
et al., 2001). As seen in lane 8 of Figure 5c, an antibody
against RBP-Jk included in the binding reactions markedly
reduced the intensity of complex B but had little effect on
complex A, suggesting that indeed RBP-Jk participated in the
formation of complex B. A number of other antibodies
against DNA-binding transcription factors were also tested,
for example NF-kB p50, p52 and p65, c-jun, Oct1, ets (data
not shown) but did not affect the assembly of the complexes
on S-70 or S-35.
The question then was whether complex A and/or B
contained hRoDH-E2. When the binding reactions were
carried out in the presence of hRoDH-E2 antibody, we
observed a complete supershift of band A but the mobility
and intensity of complex B remained unchanged (lane 11).
Likewise, when we incubated labeled S-70 with nuclear
extract from NHEK that had been transfected with V-tagged
hRoDH-E2, the V-tag-specific antibody partially supershifted
only complex A; complex B remained unchanged (lane 10).
The physical association of hRoDH-E2, Sp1, and RBP-Jk
with the S-70 and S-35 motifs was further explored in
shift-Western experiments (Figure 5d). The DNA/protein
complexes were resolved on a polyacrylamide gel and
blotted simultaneously on two membranes. The nitrocellu-
lose membrane, which represented the protein replica of the
gel, was probed with antibodies against hRoDH-E2 (lanes
1–3), RBP-Jk (lanes 4–6), Sp1 (lanes 10–12), and an unrelated
antibody (NF-kB p50, lanes 13–15). The nylon membrane,
which retained the labeled oligonucleotides, was exposed to
X-ray film to reveal the binding profile (lanes 7–9).
Comparison between the DNA and protein signals shows
that hRoDH-E2 and Sp1 were detected only in complex A,
while RBP-Jk was present only in complex B of both S-35 and
S-70. Neither antibody revealed a protein migrating with the
mobility of the DNA/protein complexes in the lanes where no
DNA was included in the reactions (lanes 1, 4, 10, and 13).
Collectively, the results presented in Figure 5 indicate that
(1) Sp1, RBP-Jk, and hRoDH-E2 participate in complexes
assembled over S-70 and S-35 motifs. (2) Sp1 and RBP-Jk
bind to both S-70 and S-35 motifs independently of each
other. However, it is unclear to what extent the binding of
Sp1 and RBP-Jk observed in the in vitro reactions remains
independent in the context of the native promoter. (3)
hRoDH-E2 associates with Sp1 but not with RBP-Jk. At this
point, we do not know whether the interaction between Sp1
and hRoDH-E2 is direct or involves intermediary proteins.
Native profilaggrin chromatin contains hRoDH-E2/Sp1
complexes
We next examined whether hRoDH-E2 was part of the native
chromatin structure over profilaggrin promoter. Reversible
crosslinks were created with formaldehyde in live NHEK. The
isolated chromatin was immunoprecipitated with hRoDH-E2-
specific antibody, Sp1-specific antibody or the corresponding
IgY and IgG fractions, and the proximal promoter region or
the second exon of the profilaggrin gene was amplified by
PCR (Figure 6a). Consistent with the in vitro observations, the
native chromatin, immunoprecipitated with hRoDH-E2
and Sp1 antibodies, was enriched in profilaggrin proximal
promoter sequences. Very little DNA from either region
was precipitated with the non-specific immune fractions
(compare the signals from the bound and non-bound
fractions obtained after immunoprecipitation with the desig-
nated antibodies). Moreover, compared to the controls with
the respective non-immune sera, the Sp1 immunoprecipitate
was enriched in hRoDH-E2 protein and the hRoDH-E2
immunoprecipitate was enriched in Sp1 (Figure 6b).
hRoDH-E2 interferes with Sp1-dependent activation
of profilaggrin promoter
The physical association of hRoDH-E2 and Sp1 over the
profilaggrin promoter suggested that their transcriptional
activities could be interrelated. This possibility was explored
in co-transfections of NHEK with expression vectors for
hRoDH-E2 and Sp1. Forced expression of Sp1 (Figure 7a,
white bars) led to a 2-fold higher activity of the wild-type
promoter compared to the empty expression vector (black
bars). Although point mutations preventing Sp1 binding at
any one of the S-motifs decreased the promoter activity by
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more than 50% (Figure 3b), such mutations had only a
limited effect on the Sp1 activation of S-50 and S-100 mutant
reporters, most probably because interactions of the protein
at the remaining intact binding sites were sufficient to
activate the promoter. When any two of the S-motifs were
mutated simultaneously, the activity of the promoter dropped
by 90% and the Sp1 activation was completely abolished
(data not shown). Interestingly, when either S-70 or S-35
motif was mutated, the Sp1 activation was about 2-fold
higher than that of the wild-type construct, indicating that the
mutations eliminated not only a positive(s), but a negative
regulator(s), as well.
Simultaneous forced expression of hRoDH-E2 and Sp1
(shaded bars) when S-70 and S-35 were intact not only
completely prevented Sp1 activation, but also reduced the
activity of the reporters by more than 80% compared to the
mock-transfected cells. In fact, the remaining CAT activity
was two to three times lower than the activity in the presence
of hRoDH-E2 alone (striped bars). Interference of hRoDH-E2
with Sp1 activation was still evident with S-70 and S-35
mutants but was several-fold less pronounced. In this case,
the repression by Sp1 and hRoDH-E2 was equal to the
repression exerted by hRoDH-E2 alone. As evident in Figure
7b, all transfectants contained comparable amounts of Sp1
and hRoDH-E2. Assuming that no more than 30% of the
keratinocytes have been transfected, the fact that we did not
see a significant difference in the total levels of hRoDH-E2
and Sp1 indicated that (1) the co-transfection with the
respective expression vectors did not overwhelm the system
with excessively high levels of exogenous proteins. (2) The
inhibition of the Sp1-dependent activation of profilaggrin
promoter by hRoDH-E2 was not due to silencing of the
endogenous Sp1 expression. The similar amounts of V5-
tagged hRoDH-E2 also indicated that the synergistic repres-
sion exerted by Sp1 and hRoDH-E2 could not be explained
by fluctuations in the transfection efficiency. Rather, it
resulted from altered protein configuration over the promoter,
which converted Sp1 from an activator into a repressor.
hRoDH-E2 modulates the acetylation activity over profilaggrin
promoter
Consistent with such an interpretation, we observed that
hRoDH-E2 modulated the acetylation over profilaggrin
promoter. The promoter-bound protein fractions, described
in Figure 4a, were assessed for their capacity to transfer
labeled acetyl groups from acetyl co-enzyme A to histone
molecules in the presence of 10 mM sodium butyrate
(Figure 8a, black bars). Under these conditions class I/II
protein deacetylases are inhibited and class III enzymes are
inactive due to the limited amount of NAD co-enzyme.
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Figure 6. hRoDH-E2 and Sp1 associate in the native profilaggrin promoter
chromatin in live NHEK. (a) Live NHEK were treated with formaldehyde and
the crosslinked chromatin immunoprecipitated with antibodies against
hRoDH-E2, Sp1 or the corresponding non-immune sera (IgY and IgG). After
de-crosslinking 1 ng DNA isolated from the bound (B) and the non-bound
(NB) chromatin fractions was analyzed by PCR with primer pairs specific for
the promoter and exon II regions of the profilaggrin gene. The DNA (1 ng)
isolated before the immunoprecipitations (I) was amplified with the same
primers: the promoter product is shown in hRoDH-E2 line, the exon II product
in Sp1 line. (b) Prior to de-crosslinking, aliquots (10 mg by protein) from the
bound (B), non-bound (NB), and the input (IP) chromatin fractions were
boiled in SDS, resolved electrophoretically and analyzed with antibodies
against hRoDH-E2 and Sp1. The immunoprecipitating antibody is shown on
the top, the analyzing antibody is on the right of the panel. The specific
enrichment in hRoDH-E2 protein in the fractions immunoprecipitated with
the Sp1 antibody, and in Sp1 in the fractions immunoprecipitated with
hRoDH-E2 antibody is in contrast to the low amounts of these proteins in the
fractions bound to the non-immune IgY/G (NIS).
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Figure 7. hRoDH-E2 represses Sp1-dependent activation of profilaggrin
promoter. (a) The wild type (wt) and the designated mutant profilaggrin-CAT
constructs were transfected into NHEK together with expression vectors for
Sp1 (white bars), hRoDH-E2 (striped bars), or the two of them together
(shaded bars) and their CAT activities compared to those of the mock-
transfected counterparts, which were set at 100% (black bars). (b) Levels of
total hRoDH-E2, recombinant V5-tagged hRoDH-E2, total Sp1, and actin in
15mg of the whole protein extracts used in the CAT assay, as revealed by
Western blot analysis with the antibodies shown on the right. Shown are
the results for wild type (wt) and S-70 mutant (S-70) profilaggrin reporters,
co-transfected with the underlined expression vectors.
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Preincubation of the nuclear extract with excess of wild-type
oligonucleotides S-35 or S-70, or with hRoDH-E2 antibody
increased the acetylation activity that was retained over the
promoter by 50–70% compared to the untreated control. In
contrast, preincubation with an AP1 consensus oligonucleo-
tide or with Sp1 or c-jun antibody reduced the acetylation
activity by more than 2-fold. Preincubations with mutant S-70
and S-35 or with NIS had no effect. As the same preincuba-
tions had little effect on the acetylation activity of the extract
per se (data not shown), these observations reflected specific
changes in the promoter configuration elicited by the
competing oligonucleotides or antibodies. They suggest that
association of hRoDH-E2 with the S-35 and S-70 motifs
actively interferes with the recruitment and/or the activity of
protein acetylases over the promoter.
When the acetyl transferase assay was carried out in the
absence of sodium butyrate the amount of acetylated histones
in the control sample decreased by about 2-fold, indicating
that class I/II deacetylases had been recruited over the
promoter. Pretreatment of the extract with hRoDH-E2 anti-
body, however, did not lead to a difference of more than 25%
(Figure 8a, striped bars). This result could signify that
hRoDH-E2 was not significantly involved in the recruitment
of class I/II protein deacetylases or/and that the anti-
body could not interfere with their enzyme activity over the
promoter. More consistent with the first interpretation,
we observed that in live NHEK inhibition of class I/II histone
deacetylases with TSA could not alleviate hRoDH-E2-
mediated repression. Profilaggrin-driven CAT activity was
downregulated to an equal extent, regardless of the treatment
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Figure 8. hRoDH-E2 modulates the level of acetylation over profilaggrin promoter. (a) Profilaggrin promoter-bound fractions of NHEK nuclear extracts
obtained directly (P, lanes 1 and 12) or after preincubation with the designated oligonucleotides (lanes 2–6) or antibodies (lanes 7–10 and 13) were assessed for
their ability to acetylate histones in the presence (black bars) or absence (striped bars) of protein deacetylase inhibitor sodium butyrate. The results are presented
as a percentage of the activity in the control fraction (P) and are derived from four separate experiments. (b) Mock- (black and white bars) and hRoDH-E2- (wide
and narrow striped bars) transfected NHEK were treated with TSA (white- and narrow-striped bars) or solvent (black- and wide-striped bars) for 48 hours. The
CAT activity of profilaggrin and Dtk reporters, co-transfected with hRoDH-E2, is presented as a percentage of the respective mock controls. (c) The capacity for
histone acetylation of the promoter-captured (Bound) and input (IP) nuclear NHEK fractions was assessed in the presence of 1 mM NAD or 50 mM NADH, as
indicated. E2 and NIS designate the bound fractions eluted after preincubation of the extract with hRoDH-E2 antibody or chicken IgY, respectively. Sodium
butyrate was included in all reactions to inhibit class I/II deacetylases. (d). NHEK nuclear proteins were precipitated with antibodies against hRoDH-E2 (lanes 2
and 3) or SIRT1 (lanes 6 and 7) or with the respective non-immune sera (lanes 4 and 8) and the input (IP), the bound (B) and the non-bound (NB) fractions were
assayed for hRoDH-E2 and SIRT1 content by Western blotting. (e) The precipitating antibodies are shown on the top, the test antibodies are on the left. The
nuclear proteins bound to the immobilized profilaggrin promoter were analyzed for the presence of SIRT1 (top) and hRoDH-E2 (bottom). Pretreatment of the
extract with excess of S-70 oligonucleotide (S-70) or hRoDH-E2 antibody (E2 ab) markedly reduced the retention of both proteins, while pre-treatment with NIS
had very little effect. Neither protein was retained over beads that were not coupled to the promoter (beads).
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(Figure 8b), suggesting that the role of class I/II deacetylation
enzymes in hRoDH-E2 repression of profilaggrin promoter
activity may be limited. However, the inhibition of TSA-
sensitive deacetylases diminished the silencing of the Dtk
promoter by 3-fold. Thus, it appears that the actual
mechanism(s) through which hRoDH-E2 can repress tran-
scription even in one and the same cell type is influenced by
the context of the promoter.
Finally, we examined whether hRoDH-E2 might be
involved in the recruitment of class III protein deacetylases
(Figure 8c,d). To this aim the acetyl transferase reactions with
the proteins captured over profilaggrin promoter were carried
out in the presence of 10 mM sodium butyrate and supple-
mented either with class III co-enzyme NAD (1 mM) or with
its reduced form NADH (50 mM) in concentrations typical for
NHEK (Pinkas-Sarafova et al., 2005). Under these condi-
tions, the resultant acetylation activity reflects the cycles of
reversible histone acetylation and deacetylation by class III
enzymes. In the presence of 1 mM NAD, concentration at
which maximal levels of deacetylation by class III histone
deacetylases could be achieved in vitro (Imai et al., 2000),
the amount of acetylated histones was reduced by 30%
compared to the control (Figure 8c). This suggested that
NAD-dependent protein deacetylases had been recruited
over the promoter and subsequently activated by the co-
enzyme. In contrast, addition of NADH to 50 mM only slightly
reduced the acetylation activity, possibly due to oxidation of
NADH during incubation. However, when using extracts
preincubated with hRoDH-E2 antibody, the amount of
acetylated histones generated by the promoter-bound fraction
in the presence of 1 mM NAD was still about 170% of the
control (comparable to that observed in the absence of NAD).
In comparison, pretreatment of the extract with NIS could not
increase the level of acetylation in the presence of 1 mM
NAD. These observations suggest that binding of hRoDH-E2
to the antibody interferes with the recruitment and/or
activation of NAD-dependent deacetylases. Consistent with
these observations, we found that hRoDH-E2 antibody co-
precipitated at least one NAD-dependent deacetylase –
SIRT1, and that immunoprecipitates of NHEK nuclear extracts
with anti-SIRT1 were enriched in hRoDH-E2 (Figure 8d).
Moreover, SIRT1 was retained over the profilaggrin promoter
and treatments, which affected hRoDH-E2 retention, resulted
in lower amounts of SIRT1, as well (Figure 8e, lanes 3 and 4).
Collectively, these results indicated that hRoDH-E2 could
affect the recruitment and/or activity of both acetylating and
deacetylating enzymes.
DISCUSSION
With the present study we have established that hRoDH-E2
can be found in the same cell in three different subcellular
compartments: In the endoplasmic reticulum, where it can
function as a retinoid and hydroxy-steroid dehydrogenase/
reductase, in the nucleus, where it has the ability to repress
promoters, and at the plasma membrane, where its function is
still unknown. The factors determining the dynamics of this
distribution are currently under investigation. It is tempting to
hypothesize that, through its ability to moonlight, hRoDH-E2
may participate in trafficking of signals between the cell
surface and the nuclear transcription apparatus.
The silencing function of hRoDH-E2 is most likely
associated with physical presence of the protein in the
nucleus. This conclusion is supported by the following
observations: First, in in vitro binding experiments with
NHEK nuclear extracts hRoDH-E2 is recruited over profilag-
grin promoter (Figure 4a). Second, the ability of the nuclear
extracts to transcribe promoters is markedly enhanced by
preincubation with hRoDH-E2 specific antibody (Figure 4b).
Third, hRoDH-E2 forms a protein complex with DNA-bound
transcription factor Sp1 at sites, which interact with at least
one other transcription regulator – RBP-Jk (Figure 5). Muta-
tions of these sites, which abolish the assembly of Sp1 and
RBP-Jk complexes in vitro, also prevent hRoDH-E2 repression
in vivo (Figure 3b). Finally, it is likely that the observed
in vitro association between hRoDH-E2 and Sp1 over profi-
laggrin promoter reproduces their interactions in vivo within
the profilaggrin promoter chromatin (Figure 6). Consistent
with this, forced expression of hRoDH-E2 completely
blocks Sp1 activation of the promoter (Figure 7a). Moreover,
although Sp1 alone acts as an activator, in combination with
hRoDH-E2 we see synergistic repression. Mutations in S-70
and S-35 prevent hRoDH-E2 repression but cannot overcome
the inhibition of Sp1 activation (Figure 7a). Collectively these
results point to a complexity in the regulatory function of S-70
and S-35. On one hand, they, together with the other two
S-motifs, positively regulate the promoter, most likely
contributing to the activation by Sp1. On the other hand,
they are clearly sites through which a negative regulator(s),
such as hRoDH-E2 can be recruited and modulate the
positive function of Sp1. Moreover, the observed interaction
of S-70 and S-35 with RBP-Jk suggests that hRoDH-E2 may
also affect the regulatory function of RBP-Jk.
hRoDH-E2 may affect transcription by modulating the
status of acetylation over the promoter (Figure 8). This is
achieved through preventing the recruitment of protein
acetylases and through active recruitment of protein deace-
tylases. It is also possible that interactions of hRoDH-E2 with
these enzymes alter their catalytic activities. The ability of
hRoDH-E2 to bind NAD(H) and the differential effect, which
these co-factors have on the overall acetylation status of the
profilaggrin promoter (Figure 8c) permit the speculation that
the repressor function of hRoDH-E2 may also be linked to the
NAD(H)-status, and hence, to the metabolic state of the cells.
The data presented herein point to a remarkable resem-
blance between hRoDH-E2 and its famous cousins in the
short chain dehydrogenase/reductase family – the COOH-
terminal binding proteins (C-terminal binding proteins
(CtBPs), see Turner and Crossley, 2001; Chinnadurai, 2002
and references therein). Both hRoDH-E2 and CtBP are
enzymes with cytoplasmic dehydrogenase activity, which
requires nicotinamide dinucleotide co-substrates (Schaeper
et al., 1995; Kumar et al., 2002; Balasubramanian et al.,
2003; Markova et al., 2003). Like hRoDH-E2, nuclear
CtBPs are potent short-range transcriptional co-repressors
(Nibu et al., 1998), which associate with many diverse
DNA-binding transcription factors and co-regulators (see
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Chinnadurai, 2002; Zhang et al., 2002; Shi et al., 2003; Kim
et al., 2005 and references therein). Although association of
CtBP with Sp1 has not been reported, Sp1-like zinc-finger
proteins were the first CtBP partners to be identified (Turner
and Crossley, 1998) and recruitment of CtBP through GT
boxes via Sp/Kruppel-like factor family has been determined
as the cause for transcriptional repression (Turner and
Crossley, 1998; van Vliet et al., 2000). Despite the extensive
efforts, the precise mechanisms by which CtBP mediates
transcriptional repression remain elusive. The CtBP com-
plexes contain components for both promoter targeting and
chromatin remodeling (Shi et al., 2003). Like hRoDH-E2,
CtBP alters the acetylation/deacetylation status of the target
promoters and both TSA-dependent and independent me-
chanisms have been implicated (Postigo and Dean, 1999; Shi
et al., 2003; Subramanian and Chinnadurai, 2003). The
ability of hRoDH-E2 (Markova et al., 2003) and CtBP
(Koipally and Georgopoulos, 2000; Kumar et al., 2002;
Zhang et al., 2002; Balasubramanian et al., 2003; Fjeld et al.,
2003) to bind NAD and its reduced and phosphorylated
forms may allow both proteins to monitor the metabolic state
of the cells in response to various internal and external stimuli
and transmit the changes to the transcription apparatus by
modulating the composition of the repressor complexes or by
regulating their own enzymatic activities.
The question of whether the enzymatic function of the
proteins is essential for their transcriptional effects has not
been resolved. It has been determined that the dehydrogen-
ase domain of CtBP is required for repression (Koipally and
Georgopoulos, 2000; Phippen et al., 2000; Kumar et al.,
2002). However, studies in which specific mutations of a
critical residue within the putative active site have been intro-
duced suggest that abolishment of the catalytic activity does
not affect transcriptional repression (Turner and Crossley,
1998; Phippen et al., 2000). Mutations in the active site of
hRoDH-E2 do not preclude its ability to silence promoters
either (Figure 2a). In fact, preliminary experiments indicate
that a region in the N-terminal third of the protein is the
domain indispensable for the repression (Markova NG,
Pinkas-Sarafova A, Karaman-Jurukovska N, and Simon M,
unpublished results). We cannot exclude that intact enzyme
activity of the protein is not a condition sine qua non for
repression but may be context- and/or cell type dependent.
Unlike CtBP, for which no specific substrate for dehydro-
genation has been uncovered, hRoDH-E2 is a dehydrogen-
ase/reductase, which actively metabolizes hydroxysteroids
and retinoids. In the epidermal keratinocytes both in vitro and
in vivo hRoDH-E2 is a major contributor to the retinol
oxidation into RA (Markova et al., 2003). Thus, irrespective of
whether or not its enzyme activity is required for transcrip-
tional repression, the dual function of hRoDH-E2 provides
another level of complexity in the retinoid (and steroid)
signaling. On one hand, the cytoplasmic hRoDH-E2
generates the active ligand RA and may thereby participate
in the activation of RA-responsive transcription. On the
other hand, by analogy with CtBP, nuclear hRoDH-E2 may
also serve as a transcriptional repressor in the presence of
liganded nuclear repressors through association with nuclear
hormone receptor co-repressors, such as RIP 140 (Vo et al.,
2001; Kumar et al., 2002) and LCoR (Fernandes et al., 2003).
Consistent with such a possibility, the N-terminus of hRoDH-E2
contains putative nuclear receptor boxes (LXXLL motifs) that
may enable it to interact with the co-repressors to attenuate
hormone-induced transactivation or repress target genes in
hormone-dependent manner (see White et al., 2004).
The binding of RBP-Jk and hRoDH-E2 (through Sp1) to
overlapping motifs within the profilaggrin promoter provides
a link between hRoDH-E2-mediated repression and another
signaling cascade – that of Notch. The transcription factor
RBP-Jk is considered the main down-stream effector of Notch
signaling (see Artavanis-Tsakonas et al., 1999). Generally,
activated Notch modulates the function of DNA-bound RBP-
Jk by mediating the composition of the regulatory complexes
assembled over the target promoters (see Lai, 2002; Mumm
and Kopan, 2002). In Drosophila a functional association
between the RBP-Jk homologue, Suppressor of hairless, and
the CtBP homologue, dCtBP, has been established as the
cause for the transcriptional repression of the single-minded
(sim) gene along the dorsoventral axis (Morel et al., 2001).
The homology of hRoDH-E2 to CtBP and the fact that
hRoDH-E2 and RBP-Jk associate with overlapping DNA
sequences within profilaggrin promoter, raise the possibility
of analogous interactions in higher eukaryotes. Perhaps
significantly, activation of Notch signaling in primary mouse
epidermal keratinocytes leads to strong downregulation of
profilaggrin expression (Rangarajan et al., 2001).
hRoDH-E2 may also be involved in tumorigenesis through
the tumor suppressor adenomatous polyposis coli – a protein
mediating the transduction of signals from the Wnt path-
way (see Polakis, 2000). A recent report (Jette et al., 2004)
suggests that the analogue of hRoDH-E2 in colon epithelium
is markedly reduced in colon cancers as a result of a
compromised adenomatous polyposis coli function. Consis-
tent with the retinol-oxidizing abilities of hRoDH-E2, the
reduction of hRoDH-E2 content is accompanied by
decreased levels of RA. The authors suggested a link between
the loss of hRoDH-E2-RA-synthesizing activity and the
malignant status. However, they did not provide evidence
that indeed increasing RA levels may alter the phenotype of
the cells or that increased RA synthesis was the sole
consequence of restoring hRoDH-E2 expression. In view of
the results that we have provided herein, it is conceivable
that a reduction in hRoDH-E2 levels may result not only in
decreased RA levels but also in direct de-repression of
transcription of key regulators in the tumor cells.
The cellular localization and the functional characteristics
of hRoDH-E2 tempt us to speculate that it may be one
converging point of three major pathways controlling
epithelial homeostasis – the retinoid, the Notch and the
Wnt. Parallel or sequential activities along the three cascades
are critical for the development and differentiation of the
epidermis (see Presland and Dale, 2000; Alonso and Fuchs,
2003; Lefort and Dotto, 2004 and references therein).
In conclusion, our data provide evidence that in addition
to its cytoplasmic dehydrogenase activity, hRoDH-E2 may be
able to act as a transcriptional repressor in the nucleus. This
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intriguing observation suggests that the effect of the protein
on the homeostasis of a given cell at any particular moment
may be a resultant of these two functions. Until they can be
clearly separated, the ability of hRoDH-E2 to moonlight
renders interpretation of results obtained from knockout and
expression interference experiments difficult. To gain an
understanding of the role of hRoDH-E2 in the cellular
homeostasis, a number of important questions must be
clarified: What are the relative contributions of the cytoplas-
mic and the nuclear functions of the protein? Are they
connected or mutually exclusive? Are they governed inde-
pendently or subject to a feedback control? What, if any,
post-translational modifications determine the cellular loca-
lization and activities of the protein and how are these
regulated? What are the partners of the cytoplasmic and the
nuclear hRoDH-E2? What are the native targets of these
interactions? Is there cell type and/or differentiation specifi-
city in the nuclear hRoDH-E2 function? Obtaining answers to
these questions may be an arduous but gratifying task.
MATERIALS AND METHODS
Approvals
The committees on research compliance for use of recombinant
DNA, and radioactive materials, the ethics committee of the State
University of New York at Stony Brook approved all described
experiments. The study was conducted according to The Declaration
of Helsinki Principles.
Plasmids and antibodies
All recombinant DNA work was carried out according to standard
procedures (Sambrook et al., 1989). The expression vectors for hRoDH-
E and hRoDH-E2 have been described (Jurukovski et al., 1999;
Markova et al., 2003). The expression vector for Sp1 was a gift from Dr
R. Tjan. The CAT reporter constructs were created as described by Jang
et al. (1996) and Lee et al. (1996). The antibody against hRoDH-E2 was
characterized in Markova et al. (2003). The antibodies against Sp1 (sc-
59), c-jun (sc-045), and CRM1 (sc-5595) were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA), against RBP-Jk (AB5790) – from
Chemicon (Temecula, CA), the anti-V5 antibody (46–0705) – from
Invitrogen (Carlsbad, CA). The agarose-immobilized anti-IgY (G119A)
and the streptavidin-magnetic beads-coupled anti-rabbit IgG (E93410)
were purchased from Promega (Madison, WI), and Dynal ASA (Oslo,
Norway), respectively. The AlexaFluor-conjugated secondary anti-
bodies, Concanavalin A and Wheat Germ Agglutinin were obtained
from Molecular Probes (Eugene, OR).
Cell cultures, transfections and CAT reporter assays
NHEK derived from neonatal foreskin were cultured and transfected
as described (Markova et al., 2003). The CAT assays were carried out
48 hours post-transfection (Jang et al., 1996). The data (mean7SD)
are an average of at least three independent experiments, each in
duplicate.
Indirect immunofluorescence and Western blot analyses
The indirect immunofluorescence was carried out on frozen sections
of foreskin epidermis or NHEK grown in chamber slides. The
specimens were fixed in formalin, permeabilized with 0.2% Triton
X-100 in phosphate-buffered saline, blocked in phosphate-buffered
saline containing 1% fetal bovine serum for at least 6 hours and then
incubated with the primary antibodies overnight at 41C and
subsequently with the secondary antibodies for 1 hour at room
temperature. Concanavalin A or wheat germ agglutinin were added
simultaneously with the secondary antibody. Epifluorescence and
confocal fluorescence microscopy were carried out at the Imaging
Center of Stony Brook Health Sciences Center, SUNY Stony Brook.
Western blot analyses were performed with nitrocellulose replicas of
proteins resolved on pre-cast gels (Invitrogen, Carlsbad, CA) and
developed with SuperSignal West Pico system (Pierce, Rockford, IL).
Preparation of nuclear extracts, bandshift, and promoter
capture experiments
NHEK nuclear extracts were prepared according to Schreiber et al.
(1989) with slight modifications: The crude nuclear pellet was
additionally washed twice with the lysis buffer A supplemented with
1% Triton X-100 to remove the perinuclear proteins. The nuclei
were then lysed in buffer C supplemented with 20% glycerol. After
removal of the nuclear debris, the soluble nuclear proteins were
aliquoted and stored at 701C until used. Bandshift experiments
were performed with 5–20 mg of nuclear extract and 3–5 104 c.p.m.
of end-labeled gel-purified double-stranded oligonucleotides in the
presence or absence of antibodies, as previously described (Rossi
et al., 1998). The sequences of the oligonucleotides were: S-35: 50-AA
GCTTCATGGGGCCTGCTACATGGGGCCTGCT ACATG-30; S-35mut:
AAGCTTCATGAAGACTGCTACATGAAGACTGCTACATG-30; S-70:
50-AAGCTTAGACCATCCCACAGACCATCCCACAGACATG-30; S-
70mut: 50-AAGCTTAGATTATCACACAGATTATCACACAGACATG-30.
The DNA protein complexes were resolved on 6% DNA retarda-
tion gels (Invitrogen, Carlsbad, CA). For the conventional bandshift
experiments, the gels were dried and exposed to X-ray film. For
the shift-Western experiments, after electrophoresis the gels were
blotted simultaneously on a nitrocellulose and a nylon membrane
(Demczuk et al., 1993). The DNA replicas were exposed to X-ray
film and the protein replicas were probed with antibodies. For the
promoter-capture experiments, the profilaggrin promoter fragments
147/þ 9 or exon II (Markova et al., 1993) were biotinylated at one
of their 50-ends and retained over streptavidin-magnetic beads. The
beads were incubated overnight with 500 mg NHEK nuclear extract
and the specifically bound material was eluted and subjected to
Western blot and histone acetylation analyses as described by
Masumi et al. (1999) and Ogryzko et al. (1996).
In vitro transcription
The in vitro transcription experiments were carried out using
HeLaScribe Nuclear Extract in vitro Transcription System (Promega,
Madison, WI), following the manufacturer’s protocol. Linearized
plasmids (400 ng each), in which the expression of CAT is under the
control of profilaggrin promoter region 354/þ 9 (Jang et al., 1996)
or Dtk (Lee et al., 1996), were used as templates for reverse
transcription in the presence of 32[P]-rGTP. The transcripts were
purified with RNeasy Mini kit (Qiagen, Valencia, CA) and resolved
on a 6% denaturing polyacrylamide gel, dried and exposed to X-ray
film. The intensities of the bands were estimated by densitometry.
Chromatin immunoprecipitation
The chromatin immunoprecipitation experiments were carried out
according to a protocol kindly provided to us by Dr V. Russanova
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(NICHD, NIH). In brief, confluent keratinocytes were crosslinked
with formaldehyde (0.5% final concentration) added directly to
the plates for 10 minutes at room temperature. The reaction was
stopped with glycine (0.25 M final concentration). The cells were
resuspended in buffer containing 20 mM Tris, pH 8.0, 50 mM NaCl,
5 mM EDTA, 1% Triton X-100, protease inhibitors, let to swell for
30 minutes on ice and homogenized. The nuclear pellet, collected
by centrifugation, was resuspended in 10 mM Tris, pH 8.0, 0.5 M
NaCl, 1 mM EDTA, and inhibitors, centrifuged again and finally
resuspended in TE buffer, pH 8.0. Glycerol and SDS were added
to 20 and 1% final concentrations, respectively. The samples
were sonicated to achieve an average DNA fragment length of
500–1,000 bp. For immunoprecipitation, the chromatin was diluted
with 10 mM Tris, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 1% Triton
X-100 to a final SDS concentration of 0.1% and 25 mg (measured as
DNA at 260 nm) were incubated overnight with 10–50 mg antibodies
against hRoDH-E2, Sp1 or the corresponding non-immune sera,
followed by an overnight incubation with agarose-conjugated anti-
chicken IgY for hRoDH-E2 reactions and magnetic beads-coupled
anti-rabbit IgG for Sp1 reactions. The bound material was eluted
with 1% SDS at 371C. The crosslinks were reversed by an overnight
incubation at 651C. The proteins in the eluates were analyzed
by Western blotting. To isolate the immunoprecipitated DNA, the
samples were digested with proteinase K in 0.1% SDS at 451C for
4 hours and DNA was purified with Qiagen PCR Purification Kit.
Specific sequences were amplified with FastStart Taq DNA
Polymerase (Roche Diagnostics, Indianapolis, IN). The conditions
of the PCR were optimized in advance with input DNA. Primers
spanning sequences 144/127 (forward) and þ 8/11 (reverse)
and þ 9767/þ 9792 (forward) and þ 10577/þ 10552 (reverse) were
used to amplify the promoter region (see Figure 3a), and exon II
(Markova et al., 1993) of the profilaggrin gene, respectively. The
resulting DNA fragments were resolved on denaturing DNA gels
(Invitrogen, Carlsbad, CA).
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